Reznik G K, Padberg G
Institute for Pathology and Toxicology, BYK Gulden Pharmaceuticals, Hamburg, Federal Republic of Germany.
J Cancer Res Clin Oncol. 1991;117(2):123-9. doi: 10.1007/BF01613135.
The aim of this study was to produce large liver tumors reliably, and to diagnose the tumors during development. Therefore, New Zealand white rabbits were treated with N-nitrosodiethylamine orally three times per week by gavage and were examined by clinical-chemical assay at regular intervals during the average treatment period of 14 months. The total cumulative dose was 1200 mg N-nitrosodiethylamine over 14 months. After a short treatment period the initial dose of 3 mg/kg had to be reduced to 1.5 mg/kg. In all 11 treated animals (100%) liver tumors were seen at the end of the study. Four control animals did not show any neoplastic changes. Clinical parameters investigated were for an assessment of liver function, total protein, urea, creatinine, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, albumin and neuraminic acid as well as some serum electrolytes. The in vivo diagnosis of liver tumors based on changes in these parameters proved to be relatively unreliable. The liver enzyme tests and urea concentration only yielded significant changes when the liver tumors were very large. Changes in neuraminic acid levels were the most reliable indicator for the presence of a liver tumor in this animal model. In the 11 treated animals, serum values of this marker increased towards the end of the study by an average of 300 mg/dl. The induced tumors were mainly hepatocellular carcinomas. Only in 1 animal was a hepatocellular adenoma found. Further primary tumors diagnosed were six adenomas in the kidneys and two uterus adenomas, as well as nasal cavity tumors (two papillomas, one carcinoma, one adenoma and one adenocarcinoma). In 70% of the treated rabbits the hepatocellular carcinomas had metastasized to the lungs.
本研究的目的是可靠地诱导出大型肝肿瘤,并在肿瘤发展过程中进行诊断。因此,给新西兰白兔每周经口灌胃3次N-亚硝基二乙胺,并在平均为期14个月的治疗期间定期进行临床化学检测。在14个月内,N-亚硝基二乙胺的总累积剂量为1200mg。在短时间治疗后,初始剂量3mg/kg不得不降至1.5mg/kg。在研究结束时,所有11只接受治疗的动物(100%)均出现了肝肿瘤。4只对照动物未显示任何肿瘤性变化。所研究的临床参数包括用于评估肝功能的总蛋白、尿素、肌酐、丙氨酸转氨酶、天冬氨酸转氨酶、碱性磷酸酶、白蛋白和神经氨酸,以及一些血清电解质。基于这些参数变化对肝肿瘤进行的体内诊断被证明相对不可靠。只有当肝肿瘤非常大时,肝酶检测和尿素浓度才会出现显著变化。神经氨酸水平的变化是该动物模型中肝肿瘤存在的最可靠指标。在11只接受治疗的动物中,该标志物的血清值在研究接近结束时平均升高了300mg/dl。诱导产生的肿瘤主要是肝细胞癌。仅在1只动物中发现了肝细胞腺瘤。进一步诊断出的原发性肿瘤包括6个肾腺瘤、2个子宫腺瘤以及鼻腔肿瘤(2个乳头状瘤、1个癌、1个腺瘤和1个腺癌)。在70%接受治疗的兔子中,肝细胞癌已转移至肺部。